- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05549752
Flecainide Versus Amiodarone in the Cardioversion of Paroxysmal Atrial Fibrillation at the Emergency Department, in Patients With Coronary Artery Disease Without Residual Ischemia (FLECA-ED)
Safety and Efficacy of Flecainide Versus Amiodarone in the Cardioversion of Paroxysmal Atrial Fibrillation at the Emergency Department, in Patients With Coronary Artery Disease Without Residual Ischemia and Ejection Fraction > 35%
Current guidelines for the cardioversion of paroxysmal Atrial Fibrillation at the Emergency Department do not prioritize between antiarrhythmic agents and do not consider the time taken for successful cardioversion. Furthermore, the use of flecainide -a class 1C antiarrhythmic agent- is contraindicated for the cardioversion of patients with revascularized coronary artery disease, as well as patients with ischemic cardiomyopathy and preserved ejection fraction. These recommendations stem from insufficient data, mainly from the CAST study.
The present study is a prospective, multicentre, randomized clinical trial. The primary goals of this clinical trial are to prove the superiority of flecainide over amiodarone in the successful cardioversion of paroxysmal atrial fibrillation at the Emergency Department, and to prove that the safety of flecainide is non-inferior to amiodarone, in patients with coronary artery disease without residual ischemia and ejection fraction over 35%. The secondary goals of the study are to prove the superiority of flecainide over amiodarone in the reduction of hospitalizations from the Emergency Department due to atrial fibrillation, in the time taken to achieve cardioversion, and to the reduction of the need to conduct electrical cardioversion.
The study population will be all consecutive new-comers to the Emergency Department with primary diagnosis of paroxysmal atrial fibrillation and history of coronary artery disease without angina, without residual ischemia and with ejection fraction > 35%. The sample size will be 200 patients, who will be monitored for 30 days. At the Emergency Department, all patients will be under continuous ECG monitoring, and a 24-hour ECG device will also be placed (Holter). The patients will be randomized to the treatment group (flecainide) and the control group (amiodarone).
Patients in both arms will stay at the ED for a total of 6 hours after therapy initiation. If no adverse events occur in this time, the patient will be discharged from the ED. Otherwise, the patient will be admitted to the hospital. At 24 hours, the patients will visit the study centre for physical examination, ECG, cardiac ultrasound, 24-hour ECG removal and adverse events evaluation. At 30 days, follow-up via phone calls will be conducted for the evaluation of the study outcomes and adverse events.
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Athens, Greece, 11527
- Recruiting
- First Department of Cardiology, Hippocration General Hospital, National and Kapodistrian University of Athens, Athens, Greece
-
Athens, Greece, 12462
- Not yet recruiting
- Attikon General Hospital of Athens
-
-
Attiki
-
Athens, Attiki, Greece, 15125
- Not yet recruiting
- Athens Heart Center Amarousion
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age: 18-85 years old
Paroxysmal Atrial Fibrillation, documented by 12-lead ECG, with one of the following:
- Atrial Fibrillation onset less than 48 hours from the time of presentation to the Emergency Department
- Atrial Fibrillation onset between 48 hours and 7 days from the time of presentation to the Emergency Department, and patient has been on anticoagulation for at least 30 days
History of Coronary Artery Disease without residual ischemia, defined by one of the following criteria:
- PCI <= 1 year, or
- CABG <= 3 years, or
Negative imaging-based stress testing within 1 year, and:
- History of known coronary artery stenosis > 60% without revascularization, or
- PCI >= 1 year, or
- CABG >= 3 years
- Ejection Fraction > 35% (documented by cardiac ultrasound at the Emergency Department, or within 1 year)
- Signed informed consent from the patient or legal representative.
Exclusion Criteria:
Based on ECG at the Emergency Department:
- Atrial Flutter
- Newly documented Left Bundle Branch Block (LBBB)
- Newly documented Right Bundle Branch Block (RBBB) with QRS duration > 150ms
- Previously documented 24-hour ECG holter monitoring with > 720 poly PVCs/24hours, or non sustained ventricular tachycardia
- No history of coronary artery disease
- ST-Segment Elevation Myocardial Infarction (STEMI)
Non-ST-Segment Elevation Myocardial Infarction (NSTEMI), according to ESC 2020 guidelines on NSTEMI:
- If troponin at t0h is over the "low" criterion on table of the cutoff values
- If the change of troponin (Δtroponin) at t1h is over the respective cutoff value at the table for the cutoff values
- Unstable angina, defined as myocardial ischemia at rest or at minimum effort, in the absence of acute injury/necrosis of myocardial cells
Known residual ischemia:
- Positive imaging-based stress testing
Negative imaging-based stress testing >= 1 year, and:
- History of known coronary artery stenosis > 60% without revascularization, or
- PCI >= 1 year, or
- CABG >= 3 years
- History of acute coronary syndrome within 1 year
- Severe Aortic Valve Stenosis (mean pressure gradient > 40mmHg, AVA < 1cm/m^2)
- Severe Chronic Kidney Disease (stage >= 4)
- Severe systematic disease, including neoplasmatic disease under any antineoplasmatic treatment, liver failure, infection with fever
- Use of strategy "pill in the pocket", by taking flecainide (max 200mg) or propafenone (max 600mg) within 6 hours prior to Emergency Department visit
- Known dysanexia or allergy to flecainide or amiodarone
- Pregnancy or/and breastfeeding
- Participation in any other clinical trial
- Life expectancy less than 1 year
- Inappropriate, unfit, or unwilling to follow the desingated protocol procedures.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Amiodarone
|
Intravenous Amiodarone at a dose of 5.0-7.0 mg/kg for 1 hour, and maintenance dose of 50mg/h (maximum dose: 1000mg) for up to 24 hours.
|
Active Comparator: Flecainide
|
Intravenous Flecainide at a dose of 2.0mg/kg (maximum dose: 150mg) in 100ml D/W 5% for 10 minutes.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The frequency of successful cardioversion to sinus rhythm
Time Frame: From the drug initiation and for 6 hours
|
From the drug initiation and for 6 hours
|
The combined frequency of premature ventricular contractions (PVCs), non-sustained ventricular tachycardia (NSVT), sustained ventricular tachycardia (SVT), bradycardia < 50bpm and systolic blood pressure < 90mmHg.
Time Frame: From the drug initiation and for 6 hours
|
From the drug initiation and for 6 hours
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The frequency of patient discharges from the Emergency Department in sinus rhythm
Time Frame: From the drug initiation and for 6 hours
|
From the drug initiation and for 6 hours
|
The frequency of successful cardioversion to sinus rhythm
Time Frame: From the drug initiation and for 24 hours, 24 hour ECG Holter monitoring
|
From the drug initiation and for 24 hours, 24 hour ECG Holter monitoring
|
The time until the cardioversion to sinus rhythm
Time Frame: From the drug initiation and for 6 hours
|
From the drug initiation and for 6 hours
|
The frequency of electrical cardioversion
Time Frame: From the drug initiation and for 24 hours
|
From the drug initiation and for 24 hours
|
The frequency of arrhythmias: burden of PVCs, NSVT episodes, SVT episodes
Time Frame: From the drug initiation and for 24 hours
|
From the drug initiation and for 24 hours
|
The frequency, severity and type of Adverse Events
Time Frame: From the drug initiation and for 30 days
|
From the drug initiation and for 30 days
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Heart Diseases
- Cardiovascular Diseases
- Vascular Diseases
- Arteriosclerosis
- Arterial Occlusive Diseases
- Disease Attributes
- Arrhythmias, Cardiac
- Coronary Artery Disease
- Myocardial Ischemia
- Coronary Disease
- Emergencies
- Ischemia
- Atrial Fibrillation
- Molecular Mechanisms of Pharmacological Action
- Anti-Arrhythmia Agents
- Vasodilator Agents
- Enzyme Inhibitors
- Membrane Transport Modulators
- Cytochrome P-450 CYP3A Inhibitors
- Cytochrome P-450 Enzyme Inhibitors
- Voltage-Gated Sodium Channel Blockers
- Sodium Channel Blockers
- Cytochrome P-450 CYP2D6 Inhibitors
- Cytochrome P-450 CYP1A2 Inhibitors
- Cytochrome P-450 CYP2C9 Inhibitors
- Potassium Channel Blockers
- Pharmaceutical Solutions
- Flecainide
- Amiodarone
Other Study ID Numbers
- FLECA-ED
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Atrial Fibrillation Paroxysmal
-
Medtronic Cardiac Rhythm and Heart FailureCompletedParoxysmal Atrial Fibrillation (PAF)United States, Canada
-
Biosense Webster, Inc.Active, not recruitingRefractory Paroxysmal Atrial FibrillationChina
-
Boston Scientific CorporationCompletedParoxysmal Atrial Fibrillation (PAF)United States, Spain, Germany, Australia, United Kingdom, Sweden, Czechia, France, Portugal
-
Charite University, Berlin, GermanyGerman Federal Ministry of Education and ResearchTerminatedSymptomatic Paroxysmal Atrial FibrillationGermany
-
Biosense Webster, Inc.RecruitingDrug Refractory Paroxysmal Atrial FibrillationUnited States
-
Hospital Clinic of BarcelonaCompletedDrug-refractory Paroxysmal Atrial FibrillationSpain
-
Ablacon, Inc.RecruitingAtrial Fibrillation | Arrhythmias, Cardiac | Arrhythmia | Atrial Flutter | Atrial Fibrillation, Persistent | Atrial Tachycardia | Atrial Arrhythmia | Atrial Fibrillation Paroxysmal | Atrial Fibrillation, Paroxysmal or PersistentUnited States, Belgium, Netherlands, Czechia
-
Biosense Webster, Inc.CompletedDrug Refractory Symptomatic Paroxysmal Atrial FibrillationUnited States
-
Medtronic Cardiac Rhythm and Heart FailureMedtronic Atrial Fibrillation SolutionsCompletedSymptomatic Paroxysmal Atrial Fibrillation Without Clinically Significant Heart DiseasesNetherlands, Australia, France, Norway, Germany, Croatia, Italy, Argentina, Belgium
-
Beijing Anzhen HospitalJohnson & Johnson; Heart Health Research CenterNot yet recruitingParoxysmal Atrial Fibrillation | Persistent Atrial Fibrillation
Clinical Trials on Flecainide Injectable Solution
-
Alcon ResearchTerminatedOcular Hypertension | Open-angle Glaucoma
-
Pamukkale UniversityCompletedPrimary DysmenorrheaTurkey
-
Maturi, Raj K., M.D., P.C.CompletedAge Related Macular DegenerationUnited States
-
University of EdinburghNHS LothianWithdrawnBronchiectasis | Immunoglobulin Subclass DeficiencyUnited Kingdom
-
Ribomic USA IncCompletedAge-related Macular DegenerationUnited States
-
Connecticut Children's Medical CenterRecruitingPost-operative Pain | MacromastiaUnited States
-
RegeneRx Biopharmaceuticals, Inc.WithdrawnST Elevation Myocardial Infarction | Acute Myocardial Infarction | STEMI
-
Wolfson Medical CenterSanofi; Assaf-Harofeh Medical CenterUnknown
-
Dove Medical Press LtdHainan Medical CollegeCompleted
-
Nakhia Impex LLCMongolian National University of Medical SciencesCompleted